Effect of Acorus calamus L. Polysaccharide on CD274 and CD326 Expression by Lewis Lung Carcinoma Cells in Mice
- Authors: Lopatina K.A.1,2, Safonova E.A.1, Nevskaya K.V.3, Stakheeva M.N.4, Gur’ev A.M.3, Zueva E.P.1, Razina T.G.1, Amosova E.N.1, Krylov S.G.1, Belousov M.V.3
-
Affiliations:
- Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
- Laboratory of Phytochemistry of Siberian Botanical Garden of National Research Tomsk State University
- Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation
- Laboratory of Molecular Oncology and Immunology, Research Institute of Oncology, Tomsk National Research Medical Center
- Issue: Vol 164, No 1 (2017)
- Pages: 102-105
- Section: Article
- URL: https://journals.rcsi.science/0007-4888/article/view/239398
- DOI: https://doi.org/10.1007/s10517-017-3934-4
- ID: 239398
Cite item
Abstract
Tumor cells can maintain their growth via immunosuppression and escape from host antitumor immunity by controlling the PD-1/PD-L1 system. Expression of PD-L1 (CD274) is an inhibitory signal for T cells, while the increase in CD326 expression in the tumor tissue correlates with metastasis development. The experimental preparation on the basis of α(1,2)-L-rhamno-α(1,4)-D-galactopyranosyluronan from Acorus calamus L. produces an antitumor effect: it reduces tumor node size and the number and area of metastases after transplantation of Lewis lung carcinoma. Using flow cytometry, we demonstrated a decrease in the population of tumor cells expressing surface CD274 (PD-L1) and CD326 antigens after 20-day course of α(1,2)-L-rhamno-α(1,4)-D-galactopyranosyluronan.
About the authors
K. A. Lopatina
Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center; Laboratory of Phytochemistry of Siberian Botanical Garden of National Research Tomsk State University
Author for correspondence.
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk; Tomsk
E. A. Safonova
Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk
K. V. Nevskaya
Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk
M. N. Stakheeva
Laboratory of Molecular Oncology and Immunology, Research Institute of Oncology, Tomsk National Research Medical Center
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk
A. M. Gur’ev
Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk
E. P. Zueva
Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk
T. G. Razina
Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk
E. N. Amosova
Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk
S. G. Krylov
Laboratory of Oncopharmacology, E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk
M. V. Belousov
Department of Pharmaceutical Analysis, Centre for Introduction of Technologies, Siberian State Medical University, Ministry of Health of the Russian Federation
Email: k.lopatina@pharmso.ru
Russian Federation, Tomsk